A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks ...
A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks ...
Mr. Camburn, a former Novartis sales executive, claims the company used speaker events and excessive compensation to influence doctors' prescribing practices, violating the Antitrust Kickback Statute.
Investigations Newsletter: Second Circuit Partially Affirms Novartis’ Motion to Dismiss AKS Claims
Second Circuit Partially Affirms Novartis’ Motion to Dismiss AKS Claims - Last week, the Second Circuit Court of Appeals affirmed ...
Recent health developments include a new injectable cancer drug by Bristol Myers Squibb, a revived lawsuit against Novartis ...
Recent health developments include the FDA's approval of an injectable version of Bristol Myers Squibb's cancer drug Opdivo.
A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed. The case furthe ...
Novartis agreed in 2020 to pay more than $729 million to settle U.S. government charges it paid illegal kickbacks to doctors and patients to boost drug sales. The case is US ex rel Camburn v.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback